Johnson & Johnson announced that it had obtained FDA approval for its HIV drug Symtuza (darunavir).

Approval for the treatment of patients with HIV comes on the heels of two phase 3 trials where Symtuza was shown to maintain virological suppression in 95% of the patients.

It expected that Biktarvy could reach peak sales between $6 to $10 billion, which means Symtuza has the potential to earn a good chunk of that.

Symtuza is being used to treat HIV patients who have never received treatment before and for those who are already virologically suppressed on stable antiretroviral regimen.

READ FULL ARTICLE HERE